CASI Pharmaceuticals Inc Forecast, price target & analysts
CASI Pharmaceuticals Inc Target price 2025 - Analyst rating & recommendation
CASI Pharmaceuticals Inc Classifications & Recommendation:
CASI Pharmaceuticals Inc Price Target
| Target Price | $4.08 |
| Price | $1.73 |
| Potential |
135.84%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target CASI Pharmaceuticals Inc 2026 .
The average CASI Pharmaceuticals Inc target price is $4.08.
This is
135.84%
register free of charge
$4.20
142.77%
register free of charge
$4.04
133.53%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend CASI Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the CASI Pharmaceuticals Inc stock has an average upside potential 2026 of
135.84%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 28.54 | 12.75 |
| 15.76% | 55.33% | |
| Net Margin | -137.56% | -256.51% |
| 72.87% | 86.47% |
3 Analysts have issued a sales forecast CASI Pharmaceuticals Inc 2025 . The average CASI Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
3 CASI Pharmaceuticals Inc Analysts have issued a net profit forecast 2025. The average CASI Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
| 2024 | -137.56% | 72.87% |
|---|---|---|
| 2025 |
-256.51%
86.47%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.56 | -2.11 |
| 26.73% | 17.58% | |
| P/E | negative | |
| EV/Sales | 2.56 |
3 Analysts have issued a CASI Pharmaceuticals Inc forecast for earnings per share. The average CASI Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
CASI Pharmaceuticals Inc...
Current CASI Pharmaceuticals Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 19 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 09 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 19 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 09 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
